Antifungal activity of a trypsin inhibitor from Salvia hispanicaL. (chia) seeds against fluconazole-resistant strains of Candidaspp. and evaluation of its toxicity in vitro

The incidence of Candidaspecies resistant to traditional antifungal drugs is increasing globally. This issue significantly impacts patients' lives and increases healthcare expenses, confirming the need to develop novel therapeutic strategies. Recently, a thermostable trypsin inhibitor named ShTI (11.558 kDa), which has antibacterial effects on Staphylococcus aureus, was isolated from Salvia hispanicaL. (chia) seeds. This study aimed to assess the antifungal effect of ShTI against Candidaspecies and its synergism with fluconazole and to evaluate its mode of action. Preliminary toxicological studies on mouse fibroblasts were also performed. ShTI exhibited antifungal effects against C. parapsilosis(ATCC® 22,019), C. krusei(ATCC® 6258), and six clinical fluconazole-resistant strains of C. albicans(2), C. parapsilosis(2), and C. tropicalis(2). The minimum inhibitory concentration (MIC) values were 4.1 µM (inhibiting 50% of the isolates) and 8.2 µM (inhibiting 100% of the isolates). Additionally, when combined with fluconazole, ShTI had a synergistic effect on C. albicans, altering the morphological structure of the yeast. The mode of action of ShTI against C. krusei(ATCC® 6258) and C. albicansinvolves cell membrane permeabilization, the overproduction of reactive oxygen species, the formation of pseudohyphae, pore formation, and consequently, cell death. In addition, ShTI (8.65 and 17.3 µM) had noncytotoxic and nongenotoxic effects on L929 mouse fibroblasts. These findings suggest that ShTI could be a promising antimicrobial candidate, but further research is necessary to advance its application as a novel antifungal agent.